Moleculin Gets Positive FDA Feedback On Pediatric Study Plan For Annamycin In Children With R/R AML

Moleculin Biotech (MBRX) received positive feedback from the FDA on its pediatric study plan for Annamycin in children with relapsed/refractory acute myeloid leukemia (R/R AML). The FDA agreed to a single pediatric approval study evaluating Annamycin with Cytarabine as a second-line therapy, with Moleculin planning to submit a revised plan this quarter and initiate the study in the second half of 2027. This development follows the ongoing Phase 3 MIRACLE study of Annamycin plus Cytarabine in adults with R/R AML, with initial data expected in the second half of 2025.

Analysis

Moleculin Biotech (MBRX) has received constructive feedback from the U.S. Food and Drug Administration (FDA) concerning its initial pediatric study plan for Annamycin, targeting children with relapsed/refractory acute myeloid leukemia (R/R AML), a development underscored by a strong MBRX-specific sentiment score of 0.8. The FDA's agreement to a single pediatric approval study, which will evaluate Annamycin in combination with Cytarabine as a second-line therapy, signifies a potentially streamlined regulatory pathway for this challenging indication. Moleculin intends to submit a revised study plan incorporating FDA recommendations later this quarter, with the pediatric study initiation anticipated in the second half of 2027. While this positive regulatory engagement is a crucial step for Annamycin's potential pediatric application, the timeline for this program is extended. Consequently, near-term focus remains on the ongoing Phase 3 MIRACLE study of Annamycin plus Cytarabine in adults with R/R AML, which expects its initial data readout in the second half of 2025, likely serving as a more immediate and significant valuation catalyst for the company.

Key Decisions for Investors

• Investors should closely monitor the initial data readout from the adult Phase 3 MIRACLE study for Annamycin, expected in the second half of 2025, as this will be a significant near-term catalyst and provide validation for Annamycin's efficacy.
• Factor in the extended timeline for the pediatric program, with study initiation not expected until the second half of 2027, when assessing the long-term growth potential and associated capital requirements for MBRX.
• Consider the positive FDA feedback as a de-risking event for Annamycin's pediatric development pathway, potentially broadening its future market, but remain cognizant that successful clinical trial outcomes and subsequent regulatory approvals are still required.